A Phase 1b, Multicenter Trial to Evaluate Molecular Determinants of Response to Erlotinib and MK0646 in Advanced Non-Small-Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 25 Aug 2016
At a glance
- Drugs Dalotuzumab (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 09 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Nov 2010 New source identified and integrated (United Kingdom Clinical Research Network).
- 21 Jun 2010 Planned end date changed from 1 Jun 2011 to 1 May 2011 as reported by ClinicalTrials.gov.